UBS Group’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

UBS Group’s Portfolio NKGNW Stock Details NKGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,575	Closed	-$1.36K	–	10976
2024 Q4	$1.36K	Sell	13,575 -963	-7%	-$49	﹤0.01%	9256
2024 Q3	$1.03K	Buy	14,538 +932	+7%	+$83	﹤0.01%	8746
2024 Q2	$1.32K	Sell	13,606 -34	-0.2%	-$4	﹤0.01%	8594
2024 Q1	$1.64K	Buy	13,640 +34	+0.2%	+$4	﹤0.01%	8094
2023 Q4	$1.1K	Sell	13,606 -230	-2%	-$31	﹤0.01%	8399
2023 Q3	$5.46K	Buy	+13,836	New	+$5.33K	﹤0.01%	7368

Other funds holding NKGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

UBS Group's NKGNW Position: Q1 2025 in Review

UBS Group sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q1 2025, closing a stake of 13,575 shares — an estimated $1.36K sold.

UBS Group first reported a position in NKGNW in Q3 2023 and held it in 6 quarters. The position peaked at $5.46K in Q3 2023. 3 funds tracked by Wall St. Rank hold NKGNW as of Q1 2025.

UBS Group reported no remaining NKGen Biotech, Inc. Warrants position as of Q1 2025 after selling out during the quarter.
UBS Group sold 13,575 NKGen Biotech, Inc. Warrants shares in Q1 2025, an estimated $1.36K.
UBS Group first reported a position in NKGen Biotech, Inc. Warrants in Q3 2023 and held it in 6 quarters.
UBS Group's NKGen Biotech, Inc. Warrants position peaked at $5.46K in Q3 2023.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.